JPRN-jRCT2080222423
Completed
Phase 3
Dapagliflozin Effect on Cardiovascular Events. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- AstraZeneca KK
- Enrollment
- 17150
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Provision of informed consent prior to any study specific procedures
- •\- Diagnosed with Type 2 Diabetes
- •\- High Risk for Cardiovascular events
Exclusion Criteria
- •\- Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
- •\- Chronic cystitis and/or recurrent urinary tract infections
- •\- Pregnant or breast\-feeding patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Dapagliflozin in Pulmonary Arterial HypertensioPulmonary arterial hypertension.Primary pulmonary hypertensionI27. 0IRCT20200209046427N2Shahid Beheshti University of Medical Sciences100
Active, not recruiting
Phase 1
This study is being carried out to evaluate the effect of a drug calleddapagliflozin when added to current treatment for type 2 diabetes oncardiovascular events.Type 2 Diabetes mellitusMedDRA version: 20.0Level: SOCClassification code 10027433Term: Metabolism and nutrition disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-000239-28-PLAstraZeneca AB17,150
Active, not recruiting
Phase 1
This study is being carried out to evaluate the effect of a drug called dapagliflozin when added to current treatment for Type 2 diabetes on cardiovascular events.EUCTR2013-000239-28-GBAstraZeneca AB17,160
Active, not recruiting
Phase 1
Multicenter Trial to Evaluate the Effect of Dapaglliflozin on the Incidence of Cardiovascular Events (DECLARE)Type II Diabetes mellitusMedDRA version: 16.0Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2013-000239-28-ESAstraZeneca AB17,150
Active, not recruiting
Phase 1
Multicenter Trial to Evaluate the Effect of Dapaglliflozin on the Incidence of Cardiovascular Events (DECLARE)EUCTR2013-000239-28-BEAstraZeneca AB17,150